Skip to main content

Advertisement

SpringerLink
Log in

Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The mechanism of action of oncogenic or tumor suppressor microRNAs is not well understood. We examined the microRNA expression profile in completely resected lung adenocarcinoma and examined the associated response to erlotinib. The lung adenocarcinoma tissue and adjacent normal lung parenchyma of 226 stage IIB and IIIA patients who underwent complete resection were obtained for two separate retrospective cohorts. In cohort 1 (119 patients; 80 with epidermal growth factor receptor (EGFR) mutations and 39 without), miRNA microarrays were used to identify EGFR-related miRNAs and their association with survival. In cohort 2 (107 patients with EGFR mutations), the miRNAs and their association with survival and response to erlotinib were analyzed by qRT-PCR. Cox proportional hazards regression was used to evaluate the effect of treatment on survival. As a result, erlotinib is associated with a significant improvement in overall survival (P = 0.0075, cohort 1; P = 0.0372, cohort 2) and disease progression (P = 0.6929, cohort 1; P = 0.3347, cohort 2) in patients with reduced miRNA-21 expression. Additionally, miRNA-145 is strongly associated with overall survival (P = 0.0008, cohort 1; P = 0.0131, cohort 2) and progression-free survival (P = 0.0198, cohort 1; P = 0.0269, cohort 2). Understanding the response rate to erlotinib relative to miRNA-21 (77.3 vs. 41.7 %, P < 0.01) and miRNA-145 (74.1 vs. 42.6 %, P < 0.01) expression is critical. The miRNA expression profiles differed significantly between patients with and without EGFR mutations. In conclusion, lung adenocarcinoma patients with reduced miRNA-21 expression exhibit longer overall survival and a poor response rate to erlotinib. Increased miRNA-145 levels can predict overall survival, progression-free survival and excellent response rate to erlotinib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2001;51:15–36.

    Article  PubMed  CAS  Google Scholar 

  2. Tanner NT, Mehta H, Silvestri GA. New testing for lung cancer screening. Oncology. 2012;26:176–82.

    PubMed  Google Scholar 

  3. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2003;22:330–53.

    Article  PubMed  Google Scholar 

  4. Yilmaz A, Damadoglu E, Salturk C, Okur E, Tuncer LY, et al. Delays in the diagnosis and treatment of primary lung cancer: are longer delays associated with advanced pathological stage? Ups J Med Sci. 2008;113:287–96.

    Article  PubMed  Google Scholar 

  5. Yang G, Yao Y, Zhou J, Zhao Q. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer. Oncol Rep. 2012;6:2066–72.

    Google Scholar 

  6. Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol. 2007;25:4057–65.

    Article  PubMed  CAS  Google Scholar 

  7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  PubMed  CAS  Google Scholar 

  8. Farazi TA, Spitzer JI, Morozov P, Tuschl T. MiRNAs in human cancer. J Pathol. 2011;223:102–15.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Papagiannakopoulos T, Kosik KS. MicroRNAs: regulators of oncogenesis and stemness. BMC Med. 2008;6:6–15.

    Article  Google Scholar 

  10. Cheung TH, Man KN, Yu MY, Yim SF, Siu NS, et al. Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle. 2012;11:2876–84.

    Article  PubMed  CAS  Google Scholar 

  11. Duncavage E, Goodgame B, Sezhiyan A, Govindan R, Pfeifer J. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol. 2010;11:1755–63.

    Article  Google Scholar 

  12. Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, et al. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol. 2014;25:423–8.

    Article  PubMed  CAS  Google Scholar 

  13. Reungwetwattana T, Weroha SJ, Molina JR. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2012;13:252–66.

    Article  PubMed  CAS  Google Scholar 

  14. Maarten L, Janmaat ML, Rodriguez JA, Kruyt FA, Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer. 2006;118:209–14.

    Article  Google Scholar 

  15. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFR mutated lung cancer: a paradigm of molecular oncology. Oncotarget. 2010;1:497–514.

    PubMed  PubMed Central  Google Scholar 

  16. Herbst RS, Fukuoka M, Baselga J. Gefitinib—a novel targeted approach to treating cancer. Nat Rev Cancer. 2004;12:956–65.

    Article  Google Scholar 

  17. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169–81.

    Article  PubMed  CAS  Google Scholar 

  18. Costa DB, Kobayashi S. Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different? Br J Cancer. 2007;96:399 (author reply 400).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Smouse JH, Cibas ES, Janne PA, Joshi VA, Zou KH, Lindeman NI. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer. 2009;117:67–72.

    PubMed  Google Scholar 

  20. Zhong Miao, Ma Xin, Sun Caijun, et al. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chem Biol Interact. 2010;184:431–8.

    Article  PubMed  CAS  Google Scholar 

  21. Zhang T, Wang Q, Zhao D, Chen L. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci. 2011;121:437–47.

    Article  PubMed  CAS  Google Scholar 

  22. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010;39:493–506.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Krichevsky AM, Gabriely G. MiR-21: a small multi-faceted RNA. J Cell Mol Med. 2009;13:39–53.

    Article  PubMed  CAS  Google Scholar 

  24. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA. 2009;106:12085–90.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Tang Dongfang, Shen Yi, Wang Mingzhao, Yang Ronghua, Wang Zizong, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013;6:540–8.

    Article  Google Scholar 

  26. Shen Yi, Tang Dongfang, Yao Ruyong, Wang Mingzhao, Wang Yongjie, et al. microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation. Med Oncol. 2013;30:750–8.

    Article  PubMed  Google Scholar 

  27. Cho WC, Chow AS, Au JS. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer. 2009;45:2197–206.

    Article  PubMed  CAS  Google Scholar 

  28. Ma Z, Qi J, Meng S, Wen B, Zhang J. Swimming exercise training-induced left ventricular hypertrophy involves microRNAs and synergistic regulation of the PI3K/AKT/mTOR signaling pathway. Eur J Appl Physiol. 2013;113:2473–86.

    Article  PubMed  CAS  Google Scholar 

  29. Larsson E, Fredlund Fuchs P, Heldin J, Barkefors I, Bondjers C, et al. Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1. Genome Med 2009; 11:108.01-12.

  30. Cho WCS, Chow ASC, Au JSK. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer. 2009;45:2197–209.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

There is no conflict of interest for any of the authors in any aspects of the article.

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266003, China

    Guanzhong Yan, Dongfang Tang, Tong Qiu, Yi Shen, Wenjie Jiao, Yunpeng Xuan & Yongjie Wang

  2. Central Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China

    Ruyong Yao & Nan Ge

Authors
  1. Guanzhong Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruyong Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dongfang Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tong Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yi Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wenjie Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nan Ge
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yunpeng Xuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yongjie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yongjie Wang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yan, G., Yao, R., Tang, D. et al. Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib. Med Oncol 31, 203 (2014). https://doi.org/10.1007/s12032-014-0203-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0203-5

Keywords

Search

Navigation